Histone Deacetylase Inhibitors: all 1,242 studies that test it

Page 6 of 13. Open to participants first (144), then studies with results posted, then the rest; newest registration first within each.

• Determining Metabolic Effects of Valproate and Antipsychotic TherapyCompletedNCT00167934Not applicableResults posted
• Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerCompletedNCT00138203Phase 2Results posted
• Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid CancerCompletedNCT00134043Phase 2Results posted
• Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's LymphomaCompletedNCT00132028Phase 2Results posted
• Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast CancerTerminatedNCT00132002Phase 2Results posted
• Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)CompletedNCT00128102Phase 3Results posted
• A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)CompletedNCT00127127Phase 1Results posted
• An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)TerminatedNCT00127101Phase 1Results posted
• Vorinostat in Treating Patients With Metastatic or Unresectable MelanomaCompletedNCT00121225Phase 2Results posted
• Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue SarcomaCompletedNCT00112463Phase 2Results posted
• Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))CompletedNCT00111813Phase 1Results posted
• Suberoylanilide Hydroxamic Acid in Advanced Solid TumorsCompletedNCT00106626Phase 1Results posted
• A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)CompletedNCT00106431Phase 2Results posted
• Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive IodineCompletedNCT00098813Phase 2Results posted
• Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics StudyCompletedNCT00088452Phase 3Results posted
• Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT00084682Phase 2Results posted
• A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive DisorderCompletedNCT00078754Phase 2Results posted
• Valproate in Dementia (VALID)CompletedNCT00071721Phase 3Results posted
• Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and AdolescentsCompletedNCT00057681Phase 3Results posted
• Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaCompletedNCT00007345Phase 2Results posted
• Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell UlcersCompletedNCT00004412Phase 2Results posted
• Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic CancerWithdrawnNCT07488884Phase 1
• Evaluation of Intravenous Sodium Valproate on Interleukin-6 Levels in Patients With TMJ Disc DisplacementActive, not recruitingNCT07487675Phase 2
• Effect of Treatment With Butyric Acid in Anorexia NervosaActive, not recruitingNCT07289581Not applicable
• Effects of Oral Sodium Butyrate Supplementation on Body Weight Reduction in Overweight/Obese Individuals With and Without Type 2 DiabetesCompletedNCT07252609Not applicable
• Can Gut Bacteria Predict Who Benefits Most From Exercise? A Gut Supplement to Help Exercise Non-RespondersActive, not recruitingNCT07180446Not applicable
• Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe OnychomycosisActive, not recruitingNCT07065773Phase 2
• Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status EpilepticusCompletedNCT07052136Not applicable
• Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype GlioblastomasActive, not recruitingNCT06824662Early Phase 1
• A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy ParticipantsCompletedNCT06729970Phase 1
• A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).Active, not recruitingNCT06550336Phase 2
• Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell LymphomaActive, not recruitingNCT06492629Phase 2
• A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced CancersTerminatedNCT06302140Phase 1
• Valproate Versus Topiramate in MigraineCompletedNCT06248931Phase 3
• Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release TabletsCompletedNCT06214130Phase 1
• Bioavailability and Food Effect of Sodium Valproate Minitablets in Healthy Subjects.CompletedNCT06211283Phase 1
• Study of BEBT-908 in Subjects With Advanced Hematological TumorsCompletedNCT06082596Phase 1
• Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma SubjectsCompletedNCT06074107Phase 2
• To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCLActive, not recruitingNCT06072131Phase 3
• Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)SuspendedNCT06069375Phase 2
• Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT06068621Phase 2
• Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell LymphomasCompletedNCT05991973Phase 2
• Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) PatientsStatus unknownNCT05951855Phase 2
• Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerWithdrawnNCT05898828Phase 1/2
• Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid TumorsActive, not recruitingNCT05887492Phase 1/2
• CXD101 in Immunotherapy-related Liver CancerActive, not recruitingNCT05873244Phase 2
• Intestinal Microbiome-based Research for the Prevention of Acute GVHDStatus unknownNCT05808985Phase 2
• Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)TerminatedNCT05770882Phase 1/2
• Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.Status unknownNCT05749575Phase 2
• Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast CancerStatus unknownNCT05747313Phase 1/2
• Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral CapsuleActive, not recruitingNCT05716919Phase 1
• Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV ViremiaWithdrawnNCT05700630Phase 1
• The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy ChildrenStatus unknownNCT05697614Phase 4
• Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal CancerActive, not recruitingNCT05694936Phase 2
• Bioequivalence Study of Sodium Valproate and Valproic Acid TabletsActive, not recruitingNCT05641649Phase 4
• Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentActive, not recruitingNCT05627245Phase 1
• Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCCWithdrawnNCT05608369Phase 2
• Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase Ⅰb StudyCompletedNCT05586841Phase 1
• Effect of Butyrate Supplement on Rheumatoid ArthritisCompletedNCT05576597Phase 2
• Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominantCompletedNCT05526313Phase 1
• A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLCCompletedNCT05519865Phase 2
• Butyrate in Pediatric Inflammatory Bowel DiseaseCompletedNCT05456763Not applicable
• Study of Tinostamustine for Adjuvant Treatment of GlioblastomaCompletedNCT05432375Early Phase 1
• Protective Role of Pre-/ Post-biotics on Gut Inflammation, Dysbiosis, and Life Quality in Rett Syndrome (Biotics_RTT)CompletedNCT05420805Not applicable
• A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITPStatus unknownNCT05411874Phase 2
• Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.Status unknownNCT05411380Phase 2
• Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BCStatus unknownNCT05400993Phase 2
• Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical TrialStatus unknownNCT05390476Phase 2
• A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium PhenylbutyrateTerminatedNCT05349435Phase 1
• Pharmacokinetics and Safety of 'CG-745 IV' and 'CG-750' in Healthy Male AdultsCompletedNCT05345912Phase 1
• NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)CompletedNCT05340621Phase 1/2
• Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor FailureTerminatedNCT05335473Phase 1/2
• Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid LeukemiaStatus unknownNCT05330364Phase 2
• A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent GlioblastomaTerminatedNCT05324501Phase 1
• Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)TerminatedNCT05281276Phase 1
• A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic AdenocarcinomaActive, not recruitingNCT05249101Phase 1/2
• CKD-506 Drug-Drug Interaction Study in Healthy Male SubjectsCompletedNCT05238948Phase 1
• A Study to Investigate the Safety and Efficacy of RicolinostatCompletedNCT05229042Phase 1
• Evaluate the Safety and Pharmacokinetics of RicolinostatCompletedNCT05193851Phase 1
• Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 InhibitorsStatus unknownNCT05191914Phase 4
• Drug-drug Interaction Between Ciprofol and Mefanamic Acid or ValproateCompletedNCT05181007Phase 1
• Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell LymphomaStatus unknownNCT05179213Phase 2
• Binimetinib Plus Belinostat for Subjects With Metastatic Uveal MelanomaActive, not recruitingNCT05170334Phase 2
• Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial CarcinomaCompletedNCT05154994Phase 1
• A Pilot Proof of Concept Study of the Effects of Administration of SCFA in Rheumatoid Arthritis (EASi-RA)CompletedNCT05152615Not applicable
• Study of Chidamide for Steroid-resistant/Steroid-dependent Severe cGVHDStatus unknownNCT05140616Phase 1/2
• Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine NeoplasmStatus unknownNCT05113355Phase 2
• Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast CancerStatus unknownNCT05085626Phase 2
• PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell LymphomaTerminatedNCT05083208Phase 1
• Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine CarcinomaStatus unknownNCT05076786Phase 2
• Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.CompletedNCT05068427Phase 2
• A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV ReservoirsCompletedNCT05056974Phase 2
• Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast CancerStatus unknownNCT05047848Not applicable
• The Effects of Sodium Phenylbutyrate on Circulating Branched Chain Amino AcidsCompletedNCT05028803Not applicable
• Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLHStatus unknownNCT05008666Phase 2
• Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast CancerStatus unknownNCT04999540Phase 2
• Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 BlockadeStatus unknownNCT04984018Phase 2
• A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-ResminostatCompletedNCT04955340Phase 1
• A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRTTerminatedNCT04897880Phase 2
• Analysis of Microbiota Changes Induced by Microencapsulated Sodium Butyrate in Patients With Inflammatory Bowel DiseaseCompletedNCT04879914Not applicable

← Histone Deacetylase Inhibitors overview